HIMS vs LFMD

Hims & Hers retains exceptional 10x growth potential within 3-5 years, primarily driven by its scalable direct-to-consumer telehealth platform and strategic positioning in high-demand chronic care, particularly GLP-1s. The highly bullish FY2026 revenue guidance of $2.7-$2.9B (if realized) suggests a monumental acceleration in growth, fundamentally re-rating the company's future prospects. Based on...

LifeMD demonstrates compelling 10x potential, driven by its strategic focus on the high-growth GLP-1 weight management and broader telehealth market. The company boasts a scalable direct-to-consumer model and has achieved impressive gross margin expansion (87.1% in Q4 2025) and significant adjusted EBITDA improvement (up 309% YoY). Crucially, the previous major red flag of 'limited runway' and 'di...